ProShares Ultra NASDAQ Biotechnology
BIB
BIB
41 hedge funds and large institutions have $24.1M invested in ProShares Ultra NASDAQ Biotechnology in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less capital invested
Capital invested by funds: $29M → $24.1M (-$4.96M)
26% less call options, than puts
Call options by funds: $15.9M | Put options by funds: $21.6M
Holders
41
Holding in Top 10
1
Calls
$15.9M
Puts
$21.6M
Top Buyers
| 1 | +$3.14M | |
| 2 | +$1.11M | |
| 3 | +$372K | |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$294K |
| 5 |
CIA
Capital Investment Advisors
Atlanta,
Georgia
|
+$212K |
Top Sellers
| 1 | -$2.68M | |
| 2 | -$2.45M | |
| 3 | -$2.4M | |
| 4 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$1.62M |
| 5 |
CT
CMT Trading
Chicago,
Illinois
|
-$280K |